Showing 7161-7170 of 8827 results for "".
- EULAR Seeks to Classify Risk of PsA in PsO Patientshttps://practicaldermatology.com/news/eular-seeks-to-classify-risk-of-psa-in-pso-patients/2461867/New EULAR points-to-consider characterize the transition from skin to joint involvement in psoriatic disease. Overall, five overarching principles and 10 points-to-consider were formulated by a multidisciplinary task force of 30 members from 13 European countries. The principles ac
- Revian Red Hair Growth System Takes on CCCA in Second Studyhttps://practicaldermatology.com/news/revian-red-hair-growth-system-takes-on-ccca-in-second-study/2461864/Revian Red Hair Growth System is planning a second study to build on previous trial results as an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). The Revian Red Hair Growth System is a US Foof and Drug Administration- cleared, lightweight wirel
- Study: DermaSensor Correctly Identifies 96.2% of Melanomas in Senior Citizenshttps://practicaldermatology.com/news/study-dermasensor-correctly-identifies-962-of-melanomas-in-senior-citizens/2461863/DermaSensor correctly identified 96.2% of melanomas in patients 65 and older, according to a sub-analysis of the DERM-ASSESS III study data of Medicare-eligible patients that was presented at the Annual American Dermoscopy Meeting. The sensitivity of the DermaSensor device for melanoma
- Study: Men With Skin of Color Are More Likely to Die From Melanomahttps://practicaldermatology.com/news/study-men-with-skin-of-color-are-more-likely-to-doe-from-melanoma/2461853/Men with melanoma – and particularly men with skin of color – are more likely to die than women with melanoma, a new study in the Journal of the American Academy of Dermatology shows. "We know that men may be less likely to seek medical care than w
- Fecal Transplants Show Promise in Improving Response to Immunotherapy in Melanoma Patientshttps://practicaldermatology.com/news/fecal-transplants-show-promise-in-improving-response-to-immunotherapy-in-melanoma-patients/2461849/Fecal microbiota transplants (FMT) from healthy donors are safe and show promise in improving response to immunotherapy in patients with advanced melanoma, according to research in Nature Medicine. Preliminar
- WCD News: Tildrakizumab Improves Wellbeing of PsO Patientshttps://practicaldermatology.com/news/wcd-news-tildrakizumab-improves-wellbeing-of-pso-patients/2461848/Ilumetri (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis, according to research reported by Almirall, S.A. (ALM) at poster at the 25th World Congress of Dermatology in Singapore. Patients taking tild
- Laura Bush Named SDPA’s Board Presidenthttps://practicaldermatology.com/news/laura-bush-named-sdpas-board-president/2461847/Georgia-based dermatology physician assistant Laura Bush is the new president of the Society of Dermatology Physician Assistant's (SDPA) Board of Directors. Bush, a DermPA with Fayette Area Dermatology in Fayetteville, Georgia, will serve a one-year term leading the nine-membe
- RVL Launches New Prescription E-commerce Platformhttps://practicaldermatology.com/news/rvl-launches-new-prescription-e-commerce-platform/2461844/RVL Pharmaceuticals is launching a prescription e-commerce platform. ELEVATE is a secure subscription platform that allows both providers and patients to purchase RVL products. The platform comprises RVL-initiated auto refills and unlocks ad
- WCD News: Spesolimab Prevents GPP Flareshttps://practicaldermatology.com/news/wcd-news-spesolimab-prevents-gpp-flares/2461841/Spesolimab reduced the risk of generalized pustular psoriasis (GPP) flares flares by 84% over 48 weeks compared to placebo, according to late-breaking data from the EFFISAYIL™ 2 trial presebted at the at the 25th World Congress of Dermatology (WCD) in Singapore. Fur
- Nemolizumab Monotherapy Curbs Itch in Prurigo Nodularis by Week 4https://practicaldermatology.com/news/nemolizumab-monotherapy-curbs-itch-in-prurigo-nodularis-by-week-4/2461840/Nemolizumab monotherapy quickly tames itch in Prurigo Nodularis, according to a late-breaking late-breaking Phase III study presented at the 25th World Congress of Dermatology (WCD) in Singapore. Fully 19.7% of patients treated with nemolizumab monotherapy achieved an itc